Weekly injectable semaglutide significantly improves glycemic control and body weight in type 2 diabetes patients.
Background
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to chronic hyperglycemia. Despite advancements, many patients struggle to achieve optimal glycemic control and manage associated comorbidities like obesity, which exacerbates insulin resistance and cardiovascular risk. Current standard-of-care often involves multiple oral agents and insulin, but these can be limited by side effects, weight gain, and complex regimens. Glucagon-like peptide-1 receptor (GLP-1R) agonists, like semaglutide, offer a promising therapeutic avenue by enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, thereby addressing both glycemic control and weight management challenges.
Study Design
This retrospective, cross-sectional study analyzed data from 102 adult type 2 diabetes mellitus patients (57% female, 44% male; mean age 50±11.17 years) who received weekly injectable semaglutide (Ozempic) at a tertiary care hospital in Pakistan. Data was collected from January 1, 2021, to January 31, 2023. Efficacy was assessed by measuring changes in glycated haemoglobin (HbA1c), body weight, and body mass index (BMI) at 3, 6, 9, and 12 months post-initiation compared to baseline. The incidence of adverse events was also meticulously recorded. Data analysis was performed using SPSS 26 statistical software.
Results
Weekly injectable semaglutide demonstrated significant improvements across all primary efficacy endpoints. Mean values for HbA1c, body weight, and BMI were significantly different at 3, 6, 9, and 12 months post-intervention compared to baseline (p-values not specified in abstract, but stated as 'significantly different'). The study cohort had a mean diabetes duration of 8.13±6.67 years. Regarding safety, nausea was the most frequently reported adverse event, affecting 26 (25.5%) of patients. The primary reason cited for discontinuing semaglutide treatment was a perceived lack of further benefits, reported by 37 (47%) of patients who stopped the medication. This indicates a strong initial response but potential plateauing or patient perception of diminishing returns over time. The overall findings underscore semaglutide's robust impact on metabolic parameters.
Injectable semaglutide was found to be quite effective in managing type 2 diabetes mellitus, establishing it as a valuable addition to diabetes care.
Key Findings
- Weekly semaglutide significantly improved
HbA1clevels over 12 months. - Body weight and
BMIwere significantly reduced at 3, 6, 9, and 12 months. - Nausea was reported by 26 (25.5%) of patients, making it the most common adverse event.
- Lack of further perceived benefits led 37 (47%) of patients to discontinue semaglutide.
Why It Matters
This real-world retrospective study reinforces the established efficacy and safety profile of weekly injectable semaglutide in a diverse patient population, specifically within a tertiary care setting in Pakistan. For clinicians and patients, this means semaglutide is a highly effective option for achieving significant reductions in HbA1c, body weight, and BMI, even in patients with a longer duration of diabetes. The findings support its integration into existing treatment protocols for T2DM, particularly for those struggling with weight management. While the study didn't detail specific doses, the 'weekly injectable semaglutide' protocol aligns with standard Ozempic dosing. The reported tolerability, with nausea as the main side effect, is consistent with previous trials, suggesting a predictable safety profile that can be managed with dose titration. This further solidifies semaglutide's role as a cornerstone therapy for comprehensive diabetes management.
semaglutide
type-2-diabetes
obesity
glp-1-agonist
retrospective-study
glycemic-control